All In Biotech

Drug Trial Radar · NCT06824467

A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

A Phase 3, Randomized, Open-label, Multicenter Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan Maintenance Treatment With or Without Bevacizumab Versus Standard of Care After Second-line Platinum-based Doublet Chemotherapy in Participants With Platinum-sensitive Recurrent Ovarian Cancer (TroFuse-022/ENGOT-ov84/GOG-3103)

Last checked: Nov 19, 2026Latest source record: Nov 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 770 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

770

Planned (sponsor's estimate)

Start

Apr 9, 2025

Primary completion

Apr 27, 2029

Study completion Nov 9, 2032

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
Collaborators
European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
First posted
Feb 13, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Female only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

Conditions

  • Ovarian Cancer
  • Fallopian Tube Cancer
  • Primary Peritoneal Cancer

Interventions

  • Sacituzumab tirumotecanBiological

    IV Infusion

  • BevacizumabBiological

    IV Infusion

  • H1 receptor antagonistDrug

    Rescue medication taken per approved product label before sacituzumab tirumotecan

  • H2 receptor antagonistDrug

    Rescue medication taken per approved product label before sacituzumab tirumotecan

  • Acetaminophen (or equivalent)Drug

    Rescue medication taken per approved product label before sacituzumab tirumotecan

  • Dexamethasone (or equivalent)Drug

    Rescue medication taken per approved product label before sacituzumab tirumotecan

  • Steroid mouthwash (dexamethasone or equivalent)Drug

    Rescue medication taken orally 2-4 times daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part 1: Number of Participants With One or More Adverse Events (AEs)Time frame: Up to 6 weeks
  2. Part 1: Number of Participants Who Discontinue Study Intervention Due to an AETime frame: Up to 6 weeks
  3. Part 2: Progression-Free Survival (PFS)Time frame: Up to approximately 4 years

Locations

203 sites in 29 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham ( Site 0006)

    Birmingham, Alabama · Recruiting

  • Alaska Women's Cancer Care ( Site 0096)

    Anchorage, Alaska · Recruiting

  • City of Hope Comprehensive Cancer Center ( Site 0007)

    Duarte, California · Recruiting

  • City of Hope Lennar Foundation Cancer Center ( Site 0024)

    Irvine, California · Recruiting

  • Hoag Memorial Hospital Presbyterian ( Site 0019)

    Newport Beach, California · Recruiting

  • UCSF Medical Center at Mission Bay ( Site 0013)

    San Francisco, California · Recruiting

  • John Muir Health Cancer Center ( Site 0016)

    Walnut Creek, California · Recruiting

  • Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0001)

    New Haven, Connecticut · Recruiting

  • Mount Sinai Braman Comprehensive Cancer Center ( Site 0078)

    Miami Beach, Florida · Recruiting

  • Sarasota Memorial Hospital ( Site 0075)

    Sarasota, Florida · Recruiting

  • Florida Cancer Specialists East ( Site 7000)

    West Palm Beach, Florida · Recruiting

  • Winship Cancer Institute of Emory University ( Site 0086)

    Atlanta, Georgia · Recruiting

  • Augusta University - Georgia Cancer Center ( Site 0066)

    Augusta, Georgia · Recruiting

  • Parkview Research Center at Parkview Regional Medical Center ( Site 0003)

    Fort Wayne, Indiana · Recruiting

  • The University of Kansas Cancer Center - Westwood ( Site 0002)

    Westwood, Kansas · Recruiting

  • Women's Cancer Care ( Site 0067)

    Covington, Louisiana · Recruiting

  • Maine Medical Center Research Institute-MaineHealth/Maine Medical Partners - GynOnc ( Site 0008)

    Scarborough, Maine · Recruiting

  • Minnesota Oncology Hematology (MNO) ( Site 8002)

    Maplewood, Minnesota · Recruiting

  • St. Dominic's Hospital ( Site 0064)

    Jackson, Mississippi · Active not recruiting

  • Washington University School of Medicine ( Site 0052)

    St Louis, Missouri · Recruiting

  • Nebraska Methodist Hospital ( Site 0053)

    Omaha, Nebraska · Recruiting

  • John Theurer Cancer Center at Hackensack University Medical Center ( Site 0081)

    Hackensack, New Jersey · Recruiting

  • Rutgers Cancer Institute of New Jersey ( Site 0071)

    New Brunswick, New Jersey · Recruiting

  • University of New Mexico Comprehensive Cancer Center ( Site 0055)

    Albuquerque, New Mexico · Recruiting

  • NYU Langone Hospital - Long Island ( Site 0015)

    Mineola, New York · Recruiting

  • Laura and Isaac Perlmutter Cancer Center ( Site 0076)

    New York, New York · Recruiting

  • FirstHealth Cancer Center ( Site 0079)

    Pinehurst, North Carolina · Recruiting

  • University of Cincinnati Medical Center ( Site 0090)

    Cincinnati, Ohio · Recruiting

  • The James Cancer Hospital and Solove Research Institute at The Ohio State University Comprehensive C ( Site 0054)

    Columbus, Ohio · Recruiting

  • Oklahoma Cancer Specialists and Research Institute, LLC ( Site 0056)

    Tulsa, Oklahoma · Recruiting

  • Oncology Associates of Oregon, P.C.(Willamette Valley Cancer Institute) (WVCI) ( Site 8010)

    Eugene, Oregon · Recruiting

  • Allegheny Health Network West Penn Hospital ( Site 0099)

    Pittsburgh, Pennsylvania · Recruiting

  • Women & Infants Hospital ( Site 0050)

    Providence, Rhode Island · Recruiting

  • Henry-Joyce Cancer Clinic ( Site 0060)

    Nashville, Tennessee · Recruiting

  • Texas Oncology - Central/South Texas ( Site 8009)

    Austin, Texas · Recruiting

  • Texas Oncology - DFW ( Site 8001)

    Fort Worth, Texas · Recruiting

  • University Of Texas Health Science Center -San Antonio ( Site 0095)

    San Antonio, Texas · Recruiting

  • Texas Oncology - San Antonio ( Site 8005)

    San Antonio, Texas · Recruiting

  • Texas Oncology - Gulf Coast ( Site 8003)

    Webster, Texas · Recruiting

  • Virginia Cancer Specialists (VCS) ( Site 8011)

    Fairfax, Virginia · Recruiting

Showing 40 of 203 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.